Cargando…

A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy

Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Xianbin, Lu, Peng, Liu, Chuanxin, Guo, Yuzhu, Yang, Yuying, Peng, Yingying, Wang, Fangyuan, Bo, Zhichao, Dou, Xiaoxin, Shi, Haoyang, Meng, Jingyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985997/
https://www.ncbi.nlm.nih.gov/pubmed/33760188
http://dx.doi.org/10.3892/mmr.2021.12001
_version_ 1783668354304704512
author Kong, Xianbin
Lu, Peng
Liu, Chuanxin
Guo, Yuzhu
Yang, Yuying
Peng, Yingying
Wang, Fangyuan
Bo, Zhichao
Dou, Xiaoxin
Shi, Haoyang
Meng, Jingyan
author_facet Kong, Xianbin
Lu, Peng
Liu, Chuanxin
Guo, Yuzhu
Yang, Yuying
Peng, Yingying
Wang, Fangyuan
Bo, Zhichao
Dou, Xiaoxin
Shi, Haoyang
Meng, Jingyan
author_sort Kong, Xianbin
collection PubMed
description Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patients with cancer. Development of an anti-PD-1/PD-L1 sensitizer for improving response rate and effectiveness of immunotherapy is a challenge. The present study reviews the synergistic effects of PD-1/PD-L1 inhibitor with oncolytic virus, tumor vaccine, molecular targeted drugs, immunotherapy, chemotherapy, radiotherapy, intestinal flora and traditional Chinese medicine, to provide information for development of effective combination therapies.
format Online
Article
Text
id pubmed-7985997
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-79859972021-03-23 A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy Kong, Xianbin Lu, Peng Liu, Chuanxin Guo, Yuzhu Yang, Yuying Peng, Yingying Wang, Fangyuan Bo, Zhichao Dou, Xiaoxin Shi, Haoyang Meng, Jingyan Mol Med Rep Review Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patients with cancer. Development of an anti-PD-1/PD-L1 sensitizer for improving response rate and effectiveness of immunotherapy is a challenge. The present study reviews the synergistic effects of PD-1/PD-L1 inhibitor with oncolytic virus, tumor vaccine, molecular targeted drugs, immunotherapy, chemotherapy, radiotherapy, intestinal flora and traditional Chinese medicine, to provide information for development of effective combination therapies. D.A. Spandidos 2021-05 2021-03-16 /pmc/articles/PMC7985997/ /pubmed/33760188 http://dx.doi.org/10.3892/mmr.2021.12001 Text en Copyright: © Kong et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Kong, Xianbin
Lu, Peng
Liu, Chuanxin
Guo, Yuzhu
Yang, Yuying
Peng, Yingying
Wang, Fangyuan
Bo, Zhichao
Dou, Xiaoxin
Shi, Haoyang
Meng, Jingyan
A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
title A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
title_full A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
title_fullStr A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
title_full_unstemmed A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
title_short A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
title_sort combination of pd-1/pd-l1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985997/
https://www.ncbi.nlm.nih.gov/pubmed/33760188
http://dx.doi.org/10.3892/mmr.2021.12001
work_keys_str_mv AT kongxianbin acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT lupeng acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT liuchuanxin acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT guoyuzhu acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT yangyuying acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT pengyingying acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT wangfangyuan acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT bozhichao acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT douxiaoxin acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT shihaoyang acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT mengjingyan acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT kongxianbin combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT lupeng combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT liuchuanxin combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT guoyuzhu combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT yangyuying combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT pengyingying combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT wangfangyuan combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT bozhichao combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT douxiaoxin combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT shihaoyang combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy
AT mengjingyan combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy